NextTrip, Inc. (NTRP)

NASDAQ: NTRP · IEX Real-Time Price · USD
2.970
+0.220 (8.00%)
Apr 24, 2024, 12:32 PM EDT - Market closed
8.00%
Market Cap 2.78M
Revenue (ttm) 522,869
Net Income (ttm) -5.92M
Shares Out 936.43K
EPS (ttm) -10.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 609
Open 2.970
Previous Close 2.750
Day's Range 2.970 - 2.970
52-Week Range 2.390 - 11.000
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date May 13, 2024

About NTRP

NextTrip, Inc., through its subsidiaries, engages in the provision of travel technology solutions in the United States. The company offers NXT2.0, a booking engine technology platform, which provides travel distributors access to an inventory. It is also involved in the provision of online leisure travel agency services for booking hotels, flights, and curated vacations. The company was formerly known as Sigma Additive Solutions, Inc. and changed its name to NextTrip, Inc. in March 2024. NextTrip, Inc. is based in Sunrise, Florida. [Read more]

Industry Travel Services
Founded 1985
Employees 12
Stock Exchange NASDAQ
Ticker Symbol NTRP
Full Company Profile

Financial Performance

In 2022, NextTrip's revenue was $630,428, a decrease of -61.83% compared to the previous year's $1.65 million. Losses were -$8.75 million, 16.8% more than in 2021.

Financial numbers in USD Financial Statements

News

NextTrip Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program

SUNRISE, FL / ACCESSWIRE / April 2, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip", "we," "our," or the "Company"), a travel technology company, has engaged international investor relations specialis...

22 days ago - Accesswire

Neurotrope, Inc. Approves Spin-Off of Neurotrope Bioscience, Inc. and Sets Record and Distribution Dates

NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP) ("Neurotrope" or the "Company") announced today that its Board of Directors has approved the conditional distribution and set th...

3 years ago - PRNewsWire

Neurotrope Shareholders to Own 49 Percent of Petros Under Revised Merger Agreement with Metuchen

NEW YORK and MANALAPAN TOWNSHIP, N.J., Sept. 30, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company focused on innova...

3 years ago - PRNewsWire

Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company

NEW YORK and MANALAPAN TOWNSHIP, N.J., May 18, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company ("Metuchen"), focus...

4 years ago - PRNewsWire

Neurotrope Rips 150% Higher On Improved Alzheimer's Data, NIH Funding

Shares of thinly-traded microcap biopharma Neurotrope Inc (NASDAQ: NTRP) gap-opened sharply higher on above 50 times average volume following a corporate update from the company.

4 years ago - Benzinga

Neurotrope's stock plummets on heavy volume after disappointing trial of Alzheimer's treatment

Shares of Neurotrope Inc. NTRP, -77.95% plummeted 79% on heavy volume Monday, to below the $1 mark for the first time in six years, after the biopharmaceutical company said its Alzheimer's disease (AD...

5 years ago - Market Watch

Why Neurotrope Is Plunging On Heavy Volume

Shares of thinly-traded nano-cap biotech Neurotrope Inc (NASDAQ: NTRP) were plummeting Monday following an adverse clinical trial readout.

5 years ago - Benzinga